Biogen Appoints Mark Hernon as SVP, Chief Information Officer
December 04 2017 - 7:30AM
Business Wire
Biogen (NASDAQ: BIIB) announced today the appointment of Mark
Hernon as Senior Vice President, Chief Information Officer,
effective December 4.
In his new role, Mr. Hernon will lead the global information
technology (IT) organization and be responsible for accelerating
and supporting Biogen’s operations through delivery of innovative
technology capabilities, systems, and tools that align with
Biogen’s corporate strategy. Mr. Hernon joins Biogen with more than
30 years of experience in IT and strategic leadership. In recent
years with Takeda Pharmaceuticals, he was the Regional CIO for the
Americas and Global Head of R&D, QA and HR Systems, as well as
VP of Operations for the Cambridge, MA site. He was most recently
the Global Head of R&D Site Strategy and Operations, where he
led the global transformation of Takeda’s R&D footprint.
“With Mark’s years in industry successfully leading global IT
and operations functions, we are extremely pleased to have him join
us at Biogen,” said Ms. Alexander. “His experience and leadership
together with our existing excellent Biogen IT organization will
allow Biogen to continue creating and harnessing data and
information to pioneer new developments in neuroscience.”
Prior to his role with Takeda, Mr. Hernon spent 12 years with
Millennial Pharmaceuticals as CIO and VP Operations, leading
strategic initiatives to streamline the organization, aligning with
the business, and managing the group’s transition through the
acquisition by Takeda.
“I am excited at the prospect of leading a team of talented and
dedicated individuals focused on enabling Biogen’s strategy through
the smart application of technology,” said Mr. Hernon.
Mr. Hernon holds a BS and MS in Industrial and Management
Engineering from Rensselaer Polytechnic Institute, and an MBA from
the Lally School of Management at Rensselaer Polytechnic
Institute.
About BiogenAt Biogen, our mission is clear: we are
pioneers in neuroscience. Biogen discovers, develops and delivers
worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases. Founded in 1978 as one
of the world’s first global biotechnology companies by Charles
Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp,
today Biogen has the leading portfolio of medicines to treat
multiple sclerosis; has introduced the first and only approved
treatment for spinal muscular atrophy; and is focused on advancing
neuroscience research programs in Alzheimer’s disease and dementia,
neuroimmunology, movement disorders, neuromuscular disorders, pain,
ophthalmology, neuropsychiatry, and acute neurology. Biogen also
manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on
our website at www.biogen.com. To learn more, please
visit www.biogen.com and follow us on social media
– Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe HarborThis press release contains
forward-looking statements, made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to Biogen’s business activities, our
worldwide medical function and strategy, and the expected benefits
from Dr. Jariwala’s appointment as our Senior Vice President,
Worldwide. These forward-looking statements may be accompanied by
words such as “aim,” “anticipate,” “believe,” “could,” “estimate,”
“except,” “forecast,” “intend,” “may,” “plan,” “potential,”
“possible,” “will” and other words and terms of similar meaning.
You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including, without limitation: risks relating to
management and key personnel changes; failure to compete
effectively; difficulties in obtaining and maintaining adequate
coverage, pricing and reimbursement for our products; potential
future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; uncertainty of success in
developing, licensing or acquiring other product candidates or
additional indications for existing products; delay in approval of
our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of
the factors that could cause actual results to differ from our
expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in Biogen’s most recent annual or quarterly report and
in other reports Biogen has filed with the U.S. Securities and
Exchange Commission. These statements are based on our current
beliefs and expectations and speak only as of the date of this
press release. We do not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005266/en/
BiogenMEDIA:Matt Fearer, +1
781-464-3260public.affairs@biogen.comorINVESTORS:Mike Henke, +1
781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024